Tumour hypoxia – A characteristic feature with a complex molecular background

This publication has 23 references indexed in Scilit:

• Mature results from a randomized Phase II trial of cisplatin plus 5‐fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas
  Cancer, 2006
• Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study
  Radiotherapy and Oncology, 2005
• Influence of oxygen concentration and pH on expression of hypoxia induced genes
  Radiotherapy and Oncology, 2005
• The hypoxic proteome is influenced by gene-specific changes in mRNA translation
  Radiotherapy and Oncology, 2005
• Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)
  Journal of Clinical Oncology, 2005
• Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors
  Radiotherapy and Oncology, 2004
• Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors
  Radiotherapy and Oncology, 2004
• Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen
  Radiotherapy and Oncology, 2004
• Measurement of tumor oxygenation
  International Journal of Radiation Oncology*Biology*Physics, 1998
• A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
  Radiotherapy and Oncology, 1998